RESUMO
The present study systematically evaluated the efficacy and safety of Pushen capsule （PC） in the treatment of hyperlipidemia （HPL） to provide the basis for its clinical application in the future. The randomized controlled trials （RCTs） of PC in treating HPL were comprehensively retrieved from four Chinese databases and three English databases. The included RCTs were evaluated using the Cochrane risk-of-bias tool， followed by the Meta-analysis by RevMan 5.3. Twenty-four RCTs were included， with 2 634 patients involved. The patients in the experimental group were treated with PC， PC combined with conventional therapy，or PC combined with other Chinese patent medicine. The cases in the control group were treated conventionally or by other Chinese patent medicine. Meta-analysis results showed that PC alone or in combination was superior to the treatment in the control group in improving total cholesterol （TC），triglyceride （TG），high-density lipoprotein cholesterol （HDL-C），low-density lipoprotein cholesterol （LDL-C），and total response rate. Fourteen trials reported adverse reactions， including seven reporting specific results. The adverse reactions were dominated by epigastric discomfort， but the difference was not statistically significant. However， affected by the quality of the included trials，the evidence strength of the conclusion of this study is graded low. More high-quality RCTs reported in detail are needed for further confirmation.
RESUMO
Objective To explore the efficacy of pushen capsule on blood lipid and atherosclerosis in patients with ischemic stroke.Methods One hundred and twenty patients with ischemic stroke were randomly divided into three groups,treatment group (pushen capsule and rosuvastatin calcium),control group-1 (pushen capsule) and control group-2 (rosuvastatin calcium).There were 40 patients for each group.The course of treatment was 6 months.Data of serum total cholesterol (TC),triacylglycerol (TG),high density lipoprotein cholesterol (HDL-C),low density lipoprotein cholesterol (LDL-C),homocysteine (Hcy),high sensitive C reactive protein (hs-CRP),nitric oxide (NO),endothelin-1 (ET-1),the number and size of carotid plaques,and changes of intima-media thickness (IMT) were detected before and after treatment in three groups.The incidences of adverse cerebrovascular events and adverse events were observed in the three groups.And the therapeutic effects for dyslipidemia were evaluated in three groups.Results The treatment indicators were obviously improved after treatment in three groups (P ＜ 0.05).There were no significant differences in treatment indicators before treatment between three groups.The levels of TG and NO increased,the level of LDL-C,the size and thickness of carotid plaques decreased after treatment in control group-2 than those of control group-1.Levels of TC,LDL-C,Hcy,hs-CRP,ET-1,IMT,and the number,size and thickness of carotid plaques were significantly lower in treatment group than those of control group-1 (P ＜ 0.05),and the level of NO was higher in treatment group than that of control group-1 (P ＜ 0.05).Compared with control group-2,levels of TG,LDL-C,hs-CRP and the number,size and thickness of carotid plaques were significantly lower,and levels of HDL-C and NO were significantly increased in treatment group (P ＜ 0.05).There were no significant differences in the incidences of adverse drug reactions and adverse cerebrovascular events between the three groups (P ＞ 0.05).The total effective rate was higher in treatment group than that of control group-1 (P ＜ 0.05).There were no significant differences in total effective rates between treatment group and control group-2,and between control group-2 and control group-1 (P ＞ 0.05).Conclusion Pushen capsule combined with rosuvastatin calcium can obviously improve blood lipid metabolism in patients with ischemic stroke,which shows obvious antiatherosclerosis effect and good safety.